Aethlon Medical (NASDAQ:AEMD) Earns “Buy” Rating from HC Wainwright

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com initiated coverage on shares of Aethlon Medical in a research report on Monday. They set a “sell” rating on the stock.

Aethlon Medical Stock Performance

Shares of AEMD opened at $0.74 on Thursday. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.88. The firm has a market cap of $10.35 million, a P/E ratio of -0.26 and a beta of 1.61. The firm’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.45.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.